Amycretin: What Novo Nordisk's Next-Generation Weight Loss Drug Is and Isn't Yet

Amycretin is an investigational drug from Novo Nordisk, the maker of Ozempic and Wegovy, that works on two hormone systems at once rather than one. Semaglutide (the active ingredient in Ozempic and Wegovy) is a GLP-1 receptor agonist — it mimics a gut hormone that slows digestion, increases feelings of fullness, and reduces appetite. Amycretin does that too, but it's also a dual amylin receptor agonist, meaning it additionally mimics amylin, a hormone released by the pancreas alongside insulin that plays its own independent role in satiety and slows gastric emptying through a different pathway in the brainstem. The key design detail is that amycretin combines both actions in a single molecule, rather than requiring two separate drugs. That's different from CagriSema, Novo Nordisk's other dual-hormone candidate, which pairs semaglutide with a separate amylin analog called cagrilintide as a co-formulation. Amycretin is being developed in both a once-weekly subcutaneous injection and a once-daily oral pill, following the same dual-format strategy Novo Nordisk has used with semaglutide (Ozempic/Wegovy injections alongside the Rybelsus pill).

The most concrete published data comes from a Phase 1b trial of the injectable formulation, led by Lau and colleagues, which reported that participants receiving the highest tested dose lost an average of roughly 13% of their body weight over 20 weeks — a notably fast rate of loss for such an early-stage trial, though the study was small and short by the standards needed to establish long-term safety and effectiveness. Separately, Novo Nordisk shared results from an oral amycretin trial at a company research and development update in late 2024, reporting weight loss exceeding 20% at 36 weeks in a higher-dose group. That figure generated significant attention in financial and health news, but it's important to treat it with appropriate caution: it came from a company presentation rather than a peer-reviewed journal at the time it was announced, the trial population was small, and early-phase weight loss numbers don't always hold up at the same magnitude in larger, longer Phase 3 trials — this has happened with several other GLP-1-class drugs as they moved through development. As with any early-phase data, the honest takeaway is 'promising, not proven.'

Amycretin sits alongside a small group of next-generation candidates trying to beat semaglutide and tirzepatide's weight-loss results by targeting additional hormone pathways. [CagriSema](/blog/cagrisema-redefine-1-trial-results-explained) pairs semaglutide with cagrilintide as two co-formulated peptides rather than one molecule, and its REDEFINE-1 trial data showed strong weight loss, though somewhat below the very high expectations that had built up beforehand. [Retatrutide](/blog/retatrutide-triple-agonist-what-the-triumph-trials-show), from Eli Lilly, takes a different approach entirely — it's a triple agonist activating GLP-1, GIP, and glucagon receptors, and its TRIUMPH trial data has shown some of the largest average weight-loss figures reported for any candidate so far. [Survodutide](/blog/survodutide-glucagon-glp1-dual-agonist-what-trials-show) combines GLP-1 with glucagon receptor activity, a different dual mechanism again. Amycretin's distinguishing feature is being the only one of this group pairing GLP-1 with amylin in a single molecule available in both injectable and oral form — a combination Novo Nordisk is betting on partly because amylin analogs, including cagrilintide, have shown early signals of being gentler on lean muscle mass than GLP-1 alone, though this remains an active area of research rather than a settled fact.

The side effects reported in early amycretin trials look broadly similar to what's already familiar from GLP-1 medications: nausea, vomiting, diarrhea, and constipation, generally dose-dependent and more common when doses are increased quickly. This is expected, since slowing digestion is the shared mechanism behind most GLP-1-class gastrointestinal side effects, regardless of which additional hormone pathway is layered on top. What's genuinely still unknown is whether amylin's role changes this side-effect profile meaningfully in either direction — some researchers have hypothesized that amylin receptor activity could theoretically affect nausea differently than GLP-1 alone, but Phase 1b and early Phase 2 trials aren't large enough or long enough to draw firm conclusions about comparative side-effect rates, muscle preservation, or rare safety signals like pancreatitis or gallbladder issues that took larger, longer trials to characterize for semaglutide and tirzepatide. That data will come from the larger Phase 2 and Phase 3 trials still ahead.

As of early 2026, amycretin has not been approved by the FDA and is not available by prescription anywhere. It's in the mid-stage development pipeline — the general path from where it sits now through Phase 2, then Phase 3 trials (which typically run one to three years and require thousands of participants), an FDA submission, and a regulatory review typically takes several more years, even for a drug program a large company like Novo Nordisk is prioritizing. For context, semaglutide first entered clinical development in the 2000s and wasn't approved as a weight-loss treatment (Wegovy) until 2021 — a reminder that timelines in this space are almost always longer than initial headlines suggest, even for drugs backed by strong early data. It's reasonable to expect amycretin, if it clears Phase 3 successfully, to become available sometime in the latter part of this decade — but treat any more specific date circulating online with skepticism, since Novo Nordisk hasn't set one publicly and development timelines frequently shift.

No — and this is worth saying plainly. Waiting years for a drug that might, on paper, produce a somewhat larger average weight loss means delaying real, well-established health benefits from medications that are approved and available today. Semaglutide and tirzepatide have years of trial and real-world data behind them, including cardiovascular benefit data from the [SELECT trial](/blog/glp1-heart-health-what-the-select-trial-found), and choosing between [tirzepatide and semaglutide](/blog/tirzepatide-vs-semaglutide-which-works-better-2026) today is a decision your doctor can help you make with a full picture of the evidence. If a drug like amycretin is eventually approved, it will likely become one more option among several, not a categorically different experience — the fundamentals of managing side effects, protecting muscle mass, and building sustainable habits will matter just as much with any future medication as they do with the ones available right now.

New GLP-1-class drugs get announced often, and it's easy to feel like you should be waiting for the 'next big thing' instead of moving forward with what's already proven to work. If you want help thinking through where research like amycretin fits against your current treatment — or whether switching or waiting ever makes sense for your specific situation — that's worth talking through.